ClinicalTrials.Veeva

Menu

Different Norepinephrine Doses on Accuracy of Peripheral Perfusion Index in Predicting Tissue Perfusion in Septic Shock Patients

T

Tanta University

Status

Completed

Conditions

Peripheral Perfusion Index
Septic Shock

Treatments

Drug: Group I: Patients will receive norepinephrine <0.15 µg/kg/min
Drug: Group II: Patients will receive norepinephrine ≥ 0.15 µg/kg/min

Study type

Interventional

Funder types

Other

Identifiers

NCT07330908
36264MS735/11/24

Details and patient eligibility

About

This study aims to evaluate the impact of different norepinephrine doses on the accuracy of the peripheral perfusion index in predicting tissue perfusion in septic shock patients.

Primary outcome:

  • Correlation between peripheral perfusion index

Secondary outcomes:

  • Peripheral perfusion index accuracy to predict the tissue perfusion .
  • Peripheral perfusion index accuracy to predict mortality.

Full description

Septic shock is a common cause of intensive care unit admission and one of the major causes of death among intensive care unit inpatients.

It is a complex critical condition associated with a reported mortality rate of up to 30% to 40%.

. It is the most severe form of sepsis with concomitant hemodynamic failure and immune, inflammatory, and metabolic disorders. The resulting circulatory shock finally leads to an alteration of tissue perfusion, causing organ failures and associated poor outcomes.

An essential step in managing patients with septic shock is to increase systemic and regional/microcirculatory flow. Increasing arterial blood pressure with vasopressors when patients are hypotensive improves the input pressure that drives organ perfusion. Therefore, maintaining organ perfusion in the time course of septic shock is a fundamental goal.

Norepinephrine is a commonly used vasopressor in the management of septic shock. It increases vascular tone and blood pressure, thereby improving systemic perfusion. However, excessive norepinephrine dosing is associated with the risk of extreme vasoconstriction, tissue hypoperfusion, and increased mortality. Peripheral and regional tissue perfusion in patients with septic shock have been extensively studied over the last decade. Indeed, several authors have emphasized the potential benefits of monitoring microcirculatory and regional perfusion parameters to better guide the resuscitation of these patients and give a prognosis. The peripheral perfusion index ,which is defined as the ratio of the pulsatile to non-pulsatile component of the pulse oximetry plethysmograph (peripheral perfusion index = pulsatile signal/ non-pulsatile signal), is used as a simple and accurate indicator of the pulsation intensity of peripheral arterioles .

We hypothesize that peripheral perfusion index could accurately predict tissue perfusion at different doses of norepinephrine in septic shock patients. This study aims to evaluate the impact of different norepinephrine doses on the accuracy of the peripheral perfusion index in predicting tissue perfusion in septic shock patients.

Primary outcome:

  • Correlation between peripheral perfusion index

Secondary outcomes:

  • Peripheral perfusion index accuracy to predict the tissue perfusion .
  • Peripheral perfusion index accuracy to predict mortality.

Enrollment

80 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18 to 65 years.
  • Both sexes.
  • Septic shock patients requiring norepinephrine infusion at dose <0.25 µg/kg/min to achieve mean arterial pressure (Mean arterial blood pressure ≥ 65 mm Hg).

Exclusion criteria

  • Patients fail to achieve Mean arterial blood ≥ 65 mm Hg or need norepinephrine dose ≥0.25 µg /kg/min.
  • Pregnancy.
  • Diabetes mellitus.
  • Tissue edema.
  • Respiratory diseases affecting gas exchange, such as asthma and Chronic Obstructive Pulmonary Disease.
  • Sever hypoxemia or hypercarbia.
  • Core temperature < 36 ᴼc.
  • Body mass index ≥35 kg/m2
  • Cardiovascular diseases and pulmonary edema

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 2 patient groups

Group I
Experimental group
Description:
Patients will receive norepinephrine \<0.15 µg/kg/minute
Treatment:
Drug: Group I: Patients will receive norepinephrine <0.15 µg/kg/min
Group II
Experimental group
Description:
Patients will receive norepinephrine ≥ 0.15 µg/kg/minutes
Treatment:
Drug: Group II: Patients will receive norepinephrine ≥ 0.15 µg/kg/min

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems